Warning letter · FDA Warning Letters

Supersmart USA, LLC: FDA Warning Letter 706566 (Jan 21, 2026)

Agency action: Jan 21, 2026Record ID: fda_warning_-4f8dd7d5a654e475
View official source ↗

What happened

Original notice title

Supersmart USA, LLC MARCS-CMS 706566, January 21, 2026

From the archived source record

We have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. Misbranded Drugs A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Accordingly, your Super DHA product fails to bear adequate directions for its intended use, and therefore is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)]. This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
No closeout listed in FDA table
Source checked
Jul 16, 2026
Record revision
a4cebb1a7952

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
Ultra-bioactive berberine supplement: blood sugar, LDL; Celadrin Supplement – Anti-Inflammatory Formula for Joint Pain Relief; Berberine; Aminoguanidine HCL 75mg; Berberine Max Bioactivity; Glucofit; Gymnema Sylvestre; Organic Moringa; Bromelai; Diosmin Plus; Super DHA; Tart Cherry Extract
Company
Supersmart USA, LLC
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.